Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial compares how two different numbing medications help patients feel the least amount of pain while recovering from surgery.
This will be a prospective randomized controlled trial comparing the outcomes of hernia patients receiving BDE versus Exparel before abdominal wall reconstruction. The study will utilize the pain numeric rating scale (PNRS) validated questionnaire to assess pain levels. Patients will be asked to report their worst pain imaginable.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BDE for hernia patients | Active Comparator | 112.5 mg of bupivacaine, 3mg dexamethasone and 0.15 mg of epinephrine. In a 30mL syringe. This will be administered into the transversus abdominis plane on both sides. |
|
| Exparel for hernia patients | Active Comparator | 266mg (20ml) mixed with 30 mls of 0.25% marcaine, administered via syringe in the transversus abdominis plane on both sides. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BDE Injectable Drug | Drug | Bupivacaine, Dexamethasone, Epinephrine for hernia patients receiving abdominal wall reconstruction |
|
| Measure | Description | Time Frame |
|---|---|---|
| Morphine Milligram Equivalent | To evaluate the difference in medication usage/ Morphine Milligram Equivalent (MME) between the two groups | Post-Op day 1, 2, 3, 4 and 2 Week Follow-up (Day 14) |
| Pain control | Compre efficacy in pain control by using the PNRS Questionniare | Baseline, Surgery Day, Post-Op day 1, 2, 3, 4 and 2 Week Follow-up (Day 14) |
| Hospital Stay | To compare the length of hospital, stay between patients receiving BDE and those receiving Exparel. | 30-45 days after hospital discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Bowel Function | To assess the time to return of bowel function in both groups. | 30-45 days after hospital discharge |
| Total Cost | To compare the total cost between the two groups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bola Aladegbami, MD | Baylor Scott and White Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baylor University Medical Center | Dallas | Texas | 75246 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Exparel Injectable Drug | Drug | Exparel for hernia patients receiving abdominal wall reconstruction |
|
| 30-45 days after hospital discharge |